A medication called oxybutynin designed to target overactive bladder could soon become available over the counter. This will be confirmed based on the results of a Medicines and Healthcare products Regulatory Agency (MHRA) consultation.
Overactive bladder, also known as OAB, describes a condition in which you feel a frequent and sudden urge to pee, the Mayo Clinic explains.
OAB targets millions of women in the UK that could potentially benefit from the introduction of oxybutynin without a prescription.
The MHRA’s consultation is set to determine whether Aquiette 2.5mg tablets (oxybutynin hydrochloride) should be reclassified from a prescription-only medicine (POM) to a pharmacy (P) medicine.
Speaking on ITV’s This Morning, Dr Ellie said: “This is really good news.
READ MORE: Long Covid: Four symptoms women more likely to experience, according to study
